System and method for iPS cell bank using media

A method executed in a system for an iPS cell bank,

• the system comprising:
• an entry management terminal that receives a request to produce an iPS cell from a customer;
• an acceptance management terminal that manages acceptance of a somatic cell for producing the iPS cell;
• a production process management terminal that manages a step of producing the iPS cell;
• and
• a stock management terminal that manages stock of the produced iPS cell,
• the method comprising following steps executed by a first processor in the entry management terminal:
• a step of making an entry of the production request from the customer, including a desired date of collection of the somatic cell, as well as customer identification information for identifying the customer;
• a step of determining a date of collection of the somatic cell based on (i) the desired collection date included in the entered production request and (ii) a collectable date on which the somatic cell can be collected;
• a step of outputting the determined date of collection of the somatic cell to a first medium;
• and
• a step of storing, in a first memory, the determined date of collection of the somatic cell in association with the entered customer identification information;
• the method further comprising following steps executed by a second processor in the acceptance management terminal:
• a step of storing the collectable date in a second memory;
• a step of outputting the stored collectable date to a second medium;
• a step of determining a date of acceptance of the somatic cell based on (i) the date of collection of the somatic cell, transmitted by the first medium, and (ii) a period of production of the iPS cell;
• and
• a step of storing the determined date of acceptance of the somatic cell in the second memory;
• the method further comprising following steps executed by a third processor in the production process management terminal:
• a step of storing, in a third memory, a producible period during which the iPS cell can be produced;
• a step of determining a period of production of the iPS cell based on (i) the date of collection of the somatic cell, transmitted by the first medium, and (ii) the stored producible period;
• a step of determining a date of shipment of the produced iPS cell based on (i) the determined period of production of the iPS cell, and (ii) a stockable location and a stockable period where the produced iPS cell can be stocked;
• a step of outputting the determined period of production of the iPS cell to a third medium;
• and
• a step of storing the determined period of production of the iPS cell and the determined date of shipment of the iPS cell in the third memory;
• the method further comprising following steps executed by a fourth processor in the stock management terminal:
• a step of storing the stockable location and the stockable period in a fourth memory;
• a step of outputting the stored stockable location and the stored stockable period to a fourth medium;
• and
• a step of determining a stock location and a stock period for stocking the produced iPS cell based on (i) the period of production of the iPS cell, transmitted by the third medium, and (ii) the stored stockable location and stockable period,
• wherein the method further comprises following steps executed by the third processor in the production process management terminal:
• a step of registering a quality test result of the iPS cell;
• and
• a step of canceling the determined date of shipment of the produced iPS cell when the registered quality test result of the iPS cell is poor, and
• wherein the quality test comprises at least one of
• 1) cell count and survival rates;
• 2) test of purity of cells;
• 3) process-related impurities testing;
• 4) sterility testing and mycoplasma negative testing;
• 5) endotoxin testing;
• 6) viral test;
• 7) characteristic test associated with iPS cells
• (i) having pluripotency of being capable of differentiating into various somatic cells, and
• (ii) observing no gene mutation inducing cancer after transplantation, as well as low risk of tumorigenicity due to contamination of undifferentiated cells.